Cargando…

Association of Low‐Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease

BACKGROUND: The benefit of low‐density lipoprotein cholesterol (LDL‐C) levels in chronic kidney disease populations remains unclear. This study evaluated the cardiovascular and renal outcomes in patients with stage 3 chronic kidney disease with different LDL‐C levels during statin treatment. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Yen, Chieh‐Li, Fan, Pei‐Chun, Lee, Cheng‐Chia, Chen, Jia‐Jin, Kuo, George, Tu, Yi‐Ran, Chu, Pao‐Hsien, Hsu, Hsiang‐Hao, Tian, Ya‐Chung, Chang, Chih‐Hsiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673722/
https://www.ncbi.nlm.nih.gov/pubmed/36172933
http://dx.doi.org/10.1161/JAHA.122.027516
_version_ 1784833006781857792
author Yen, Chieh‐Li
Fan, Pei‐Chun
Lee, Cheng‐Chia
Chen, Jia‐Jin
Kuo, George
Tu, Yi‐Ran
Chu, Pao‐Hsien
Hsu, Hsiang‐Hao
Tian, Ya‐Chung
Chang, Chih‐Hsiang
author_facet Yen, Chieh‐Li
Fan, Pei‐Chun
Lee, Cheng‐Chia
Chen, Jia‐Jin
Kuo, George
Tu, Yi‐Ran
Chu, Pao‐Hsien
Hsu, Hsiang‐Hao
Tian, Ya‐Chung
Chang, Chih‐Hsiang
author_sort Yen, Chieh‐Li
collection PubMed
description BACKGROUND: The benefit of low‐density lipoprotein cholesterol (LDL‐C) levels in chronic kidney disease populations remains unclear. This study evaluated the cardiovascular and renal outcomes in patients with stage 3 chronic kidney disease with different LDL‐C levels during statin treatment. METHODS AND RESULTS: There were 8500 patients newly diagnosed as having stage 3 chronic kidney disease under statin treatment who were identified from the Chang Gung Research Database and divided into 3 groups according to their first LDL‐C level after the index date: <70 mg/dL, 70 to 100 mg/dL, and >100 mg/dL. Inverse probability of treatment weighting was performed to balance baseline characteristics. Compared with the LDL‐C ≥100 mg/dL group, the 70≤LDL‐C<100 mg/dL group exhibited significantly lower risks of major adverse cardiac and cerebrovascular events (6.8% versus 8.8%; subdistribution hazard ratio [SHR], 0.76 [95% CI, 0.64–0.91]), intracerebral hemorrhage (0.23% versus 0.51%; SHR, 0.44 [95% CI, 0.25–0.77]), and new‐onset end‐stage renal disease requiring chronic dialysis (7.6% versus 9.1%; SHR, 0.82 [95% CI, 0.73–0.91]). By contrast, the LDL‐C <70 mg/dL group exhibited a marginally lower risk of major adverse cardiac and cerebrovascular events (7.3% versus 8.8%; SHR, 0.82 [95% CI, 0.65–1.02]) and a significantly lower risk of new‐onset end‐stage renal disease requiring chronic dialysis (7.1% versus 9.1%; SHR, 0.76 [95% CI, 0.67–0.85]). CONCLUSIONS: Among patients with stage 3 chronic kidney disease, statin users with 70≤LDL‐C<100 mg/dL and with LDL‐C <70 mg/dL had similar beneficial effect in the reduction of risks of major adverse cardiac and cerebrovascular events and new‐onset end‐stage renal disease compared with those with LDL‐C >100 mg/dL. Moreover, the 70≤LDL‐C<100 mg/dL group seemed to have a lowest risk of intracerebral hemorrhage, although the incidence was low.
format Online
Article
Text
id pubmed-9673722
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-96737222022-11-21 Association of Low‐Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease Yen, Chieh‐Li Fan, Pei‐Chun Lee, Cheng‐Chia Chen, Jia‐Jin Kuo, George Tu, Yi‐Ran Chu, Pao‐Hsien Hsu, Hsiang‐Hao Tian, Ya‐Chung Chang, Chih‐Hsiang J Am Heart Assoc Original Research BACKGROUND: The benefit of low‐density lipoprotein cholesterol (LDL‐C) levels in chronic kidney disease populations remains unclear. This study evaluated the cardiovascular and renal outcomes in patients with stage 3 chronic kidney disease with different LDL‐C levels during statin treatment. METHODS AND RESULTS: There were 8500 patients newly diagnosed as having stage 3 chronic kidney disease under statin treatment who were identified from the Chang Gung Research Database and divided into 3 groups according to their first LDL‐C level after the index date: <70 mg/dL, 70 to 100 mg/dL, and >100 mg/dL. Inverse probability of treatment weighting was performed to balance baseline characteristics. Compared with the LDL‐C ≥100 mg/dL group, the 70≤LDL‐C<100 mg/dL group exhibited significantly lower risks of major adverse cardiac and cerebrovascular events (6.8% versus 8.8%; subdistribution hazard ratio [SHR], 0.76 [95% CI, 0.64–0.91]), intracerebral hemorrhage (0.23% versus 0.51%; SHR, 0.44 [95% CI, 0.25–0.77]), and new‐onset end‐stage renal disease requiring chronic dialysis (7.6% versus 9.1%; SHR, 0.82 [95% CI, 0.73–0.91]). By contrast, the LDL‐C <70 mg/dL group exhibited a marginally lower risk of major adverse cardiac and cerebrovascular events (7.3% versus 8.8%; SHR, 0.82 [95% CI, 0.65–1.02]) and a significantly lower risk of new‐onset end‐stage renal disease requiring chronic dialysis (7.1% versus 9.1%; SHR, 0.76 [95% CI, 0.67–0.85]). CONCLUSIONS: Among patients with stage 3 chronic kidney disease, statin users with 70≤LDL‐C<100 mg/dL and with LDL‐C <70 mg/dL had similar beneficial effect in the reduction of risks of major adverse cardiac and cerebrovascular events and new‐onset end‐stage renal disease compared with those with LDL‐C >100 mg/dL. Moreover, the 70≤LDL‐C<100 mg/dL group seemed to have a lowest risk of intracerebral hemorrhage, although the incidence was low. John Wiley and Sons Inc. 2022-09-29 /pmc/articles/PMC9673722/ /pubmed/36172933 http://dx.doi.org/10.1161/JAHA.122.027516 Text en © 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Yen, Chieh‐Li
Fan, Pei‐Chun
Lee, Cheng‐Chia
Chen, Jia‐Jin
Kuo, George
Tu, Yi‐Ran
Chu, Pao‐Hsien
Hsu, Hsiang‐Hao
Tian, Ya‐Chung
Chang, Chih‐Hsiang
Association of Low‐Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease
title Association of Low‐Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease
title_full Association of Low‐Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease
title_fullStr Association of Low‐Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease
title_full_unstemmed Association of Low‐Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease
title_short Association of Low‐Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease
title_sort association of low‐density lipoprotein cholesterol levels during statin treatment with cardiovascular and renal outcomes in patients with moderate chronic kidney disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673722/
https://www.ncbi.nlm.nih.gov/pubmed/36172933
http://dx.doi.org/10.1161/JAHA.122.027516
work_keys_str_mv AT yenchiehli associationoflowdensitylipoproteincholesterollevelsduringstatintreatmentwithcardiovascularandrenaloutcomesinpatientswithmoderatechronickidneydisease
AT fanpeichun associationoflowdensitylipoproteincholesterollevelsduringstatintreatmentwithcardiovascularandrenaloutcomesinpatientswithmoderatechronickidneydisease
AT leechengchia associationoflowdensitylipoproteincholesterollevelsduringstatintreatmentwithcardiovascularandrenaloutcomesinpatientswithmoderatechronickidneydisease
AT chenjiajin associationoflowdensitylipoproteincholesterollevelsduringstatintreatmentwithcardiovascularandrenaloutcomesinpatientswithmoderatechronickidneydisease
AT kuogeorge associationoflowdensitylipoproteincholesterollevelsduringstatintreatmentwithcardiovascularandrenaloutcomesinpatientswithmoderatechronickidneydisease
AT tuyiran associationoflowdensitylipoproteincholesterollevelsduringstatintreatmentwithcardiovascularandrenaloutcomesinpatientswithmoderatechronickidneydisease
AT chupaohsien associationoflowdensitylipoproteincholesterollevelsduringstatintreatmentwithcardiovascularandrenaloutcomesinpatientswithmoderatechronickidneydisease
AT hsuhsianghao associationoflowdensitylipoproteincholesterollevelsduringstatintreatmentwithcardiovascularandrenaloutcomesinpatientswithmoderatechronickidneydisease
AT tianyachung associationoflowdensitylipoproteincholesterollevelsduringstatintreatmentwithcardiovascularandrenaloutcomesinpatientswithmoderatechronickidneydisease
AT changchihhsiang associationoflowdensitylipoproteincholesterollevelsduringstatintreatmentwithcardiovascularandrenaloutcomesinpatientswithmoderatechronickidneydisease